Tumor Susceptibility Gene 101 (TSG101) Peptide
TSG101
Reactivity: Human
Host: Synthetic
BP, WB
Catalog No. ABIN985664
Quick Overview for Tumor Susceptibility Gene 101 (TSG101) Peptide (ABIN985664)
Target
TSG101
(Tumor Susceptibility Gene 101 (TSG101))
Origin
Human
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-TSG101 antibody (Catalog #: ARP38773_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- TSG101 (Tumor Susceptibility Gene 101 (TSG101))
-
Background
-
TSG101 belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. TSG101 contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. TSG101 may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of TSG101 appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in TSG101 gene occur in high frequency in breast cancer. The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression.
Alias Symbols: TSG10, VPS23
Protein Interaction Partner: HGS,HGS,JEVgp1,PDCD6IP,PDCD6IP,TSG101,TSG101,VPS28,VPS28,VPS28,VPS37A,VPS37B,gag,AATF,AR,CDKN1A,CEP55,DAXX,DMAP1,DNMT1,EP300,GGA1,GGA3,GMCL1,HCK,HGS,KRT15,LRSAM1,MDM2,NR3C1,PDCD6IP,PPFIBP2,SNF8,TOM1L1,TP53,UBA52,VPS28,VPS36,VPS37A,VPS37B,VPS37C,VPS37D,AR,CDKN1A,CEP55,DMAP1,EP300,GGA3,HGS,ITSN1,KIF5A,KRT15,LRSAM1,MDM2,NR3C1,PPFIBP2,SCAMP3,SCNN1A,THRB,TP53,UBC,VPS28,VPS37A,VPS37B,VPS37C
Protein Size: 390 -
Molecular Weight
- 44 kDa
-
Gene ID
- 7251
-
NCBI Accession
- NM_006292, NP_006283
-
UniProt
- Q99816
Target
-
You are here:
